The ARRY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARRY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARRY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARRY Detailed Price Forecast - CNN Money||View ARRY Detailed Summary - Google Finance|
|View ARRY Detailed Summary - Yahoo! Finance||View ARRY Stock Research & Analysis - Zacks.com|
|View ARRY Trends & Analysis - Trade-Ideas||View ARRY Major Holders - Barrons|
|View ARRY Call Transcripts - NASDAQ||View ARRY Breaking News & Analysis - Seeking Alpha|
|View ARRY Annual Report - CompanySpotlight.com||View ARRY OTC Short Report - OTCShortReport.com|
|View ARRY Fundamentals - TradeKing||View ARRY SEC Filings - Bar Chart|
|View Historical Prices for ARRY - The WSJ||View Performance/Total Return for ARRY - Morningstar|
|View the Analyst Estimates for ARRY - MarketWatch||View the Earnings History for ARRY - CNBC|
|View the ARRY Earnings - StockMarketWatch||View ARRY Buy or Sell Recommendations - MacroAxis|
|View the ARRY Bullish Patterns - American Bulls||View ARRY Short Pain Metrics - ShortPainBot.com|
|View ARRY Stock Mentions - StockTwits||View ARRY Stock Mentions - PennyStockTweets|
|View ARRY Stock Mentions - Twitter||View ARRY Investment Forum News - Investor Hub|
|View ARRY Stock Mentions - Yahoo! Message Board||View ARRY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARRY - SECform4.com||View Insider Transactions for ARRY - Insider Cow|
|View ARRY Major Holdings Summary - CNBC||View Insider Disclosure for ARRY - OTC Markets|
|View Insider Transactions for ARRY - Yahoo! Finance||View Institutional Holdings for ARRY - NASDAQ|
|View ARRY Stock Insight & Charts - FinViz.com||View ARRY Investment Charts - StockCharts.com|
|View ARRY Stock Overview & Charts - BarChart||View ARRY User Generated Charts - Trading View|
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
Posted on Wednesday July 18, 2018
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Wired News - NCCN Recommends BRAFTOVI with MEKTOVI as Category 1 Treatment Option for BRAF-Mutant Melanoma
Posted on Tuesday July 17, 2018
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Array BioPharma Inc. (NASDAQ: ARRY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARRY as the Company's latest news hit the wire. On July 13, 2018, the Company, which is a fully-integrated, biopharmaceutical Company, declared that the National Comprehensive Cancer Network (NCCN) has revised the Clinical Practice Guidelines in Oncology for Melanoma. The new guidelines make BRAFTOVI™ in combination with MEKTOVI® a Category 1 first-line and second-line treatment option for patients suffering with BRAFV600E, or BRAFV600K-mutant metastatic, or unresectable melanoma.
See what the IHS Markit Score report has to say about Array Biopharma Inc.
Posted on Saturday July 14, 2018
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $1.26 billion.
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Posted on Friday July 13, 2018
BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in ...